Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Phoenix Pharma (Site 2204)

Port Elizabeth, Eastern Cape 6001, South AfricaNot linked to an institution yet

1running trial

Running trials

Active, not recruiting
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756· Phase 3· Merck Sharp & Dohme LLC· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error

Under construction, not live – Phoenix Pharma (Site 2204): trial site – Frontlight Research